Zhang-James, Yanli http://orcid.org/0000-0002-2104-0963
Vaudel, Marc
Mjaavatten, Olav
Berven, Frode S.
Haavik, Jan
Faraone, Stephen V.
Funding for this research was provided by:
H2020 European Institute of Innovation and Technology (No 667302)
Seventh Framework Programme (no 602805)
National Alliance for Research on Schizophrenia and Depression (Young Investigator Award)
Stiftelsen Kristian Gerhard Jebsen (SKGJ-MED-002)
National Institute of Mental Health (5R01MH066877, 5R01MH101519)
Article History
Received: 20 September 2018
Accepted: 27 November 2018
First Online: 29 March 2019
Compliance with ethical standards
:
: Yanli Zhang-James, Frode S. Berven, Olav Mjaavatten, Marc Vaudel and Hanno Steen declare no conflict of interest. During the past three years, Jan Haavik has received speaker fees from Lilly, Novartis, Shire, Medice, HB Pharma and Janssen-Cilag. In the past year, Dr. Faraone received income, travel expenses and/or research support from and/or has been on an Advisory Board for Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences and research support from the National Institutes of Health (NIH). With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier, ADHD: Non-Pharmacologic Treatments.